Union make force. Reig Jofre and the biotech CZ Vaccines, from the Zendal group, have signed an agreement with the European Executive Agency for Health and Digital (Hadea) to reserve vaccine production capacity for future health emergencies.
The European Commission, through Hadea, launched a tender process with the aim of ensuring a manufacturing and supply network throughout the European Union (EU) and the European Economic Area (EEA) in order to ensure early availability of vaccines in the event of a public health emergency. The consortium formed by Reig Jofre and CZ Vaccines has been one of the four final winners in the process.
The capacity reservation agreement has been signed with an initial duration of four years. Hadea has the possibility of extending this agreement in two extensions up to a maximum duration of eight years.
Reig Jofre and CZ Vaccines have signed an agreement with Hadea for an initial period of four years
The combined capabilities of CZ Vaccines and Reig Jofre, which ensure an integrated manufacturing process, from the antigen to the final dosage form of the vaccine, together with the experience in managing a health crisis, the availability of technology and the capacity production on a large scale have been essential factors for being chosen as members of this network of European vaccine manufacturers. Both companies have committed to produce and deliver within the EU territory the doses of vaccines assigned in the contract, within a period of twelve months from the activation of an emergency situation.
CZ Vaccines of the Zendal group undertakes to reserve manufacturing capacity in its production area of O Porriño (Pontevedra, Galicia) to manufacture the active principle of the vaccine. For his part, Reig Jofre will reserve up to 30% of the maximum annual capacity of its new injectable plant located in Barcelona to meet the needs of the program.
If the reserved capacity is activated due to an emergency, both companies assume the commitment to secure the supply chain, carry out the technology transfer of the vaccine chosen by Hadea and assign the necessary technical personnel teams specifically trained in the process to satisfy the increase in demand.
In addition to the income derived from this agreement and linked to the reservation of the required manufacturing capacity, Reig Jofre will continue to promote projects, both for clients and in own products with the aim of reaching maximum production capacity of liquid and lyophilized vials.
2023-06-30 14:27:33
#Reig #Jofre #Zendal #manufacture #vaccines #Europe #case #health #emergencies
